Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells (IC50 :9.8 μM).
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 7,500 | |||
10 mg | 在庫あり | ¥ 12,000 | |||
25 mg | 在庫あり | ¥ 27,000 | |||
50 mg | 在庫あり | ¥ 45,500 | |||
100 mg | 在庫あり | ¥ 73,000 | |||
200 mg | 在庫あり | ¥ 108,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 10,000 |
説明 | CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells (IC50 :9.8 μM). |
In vitro | CCG-100602 blocks the expression of MRTF-A/SRF-activated genes. CCG-100602 (3-30?μM) decreases the number of adherent hASC cells[1]. |
分子量 | 478.82 |
分子式 | C21H17ClF6N2O2 |
CAS No. | 1207113-88-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (208.85 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CCG-100602 1207113-88-9 Cell Cycle/Checkpoint GPCR/G Protein MAPK Rho Ras Inhibitor transcription inhibit serum myocardin nuclear SRF MRTF-A localization CCG100602 CCG 100602 inhibitor